US FDA approves Pfizer’s gene therapy for rare bleeding disorder May 2, 2024 By Jennifer Newman The U.S. Food and Drug Administration approved Pfizer’s gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein.Ìý ! Filed Under: Categories: HTC News More from ºÚÁÏÍø Hemophilia and Thrombosis Center Normal operations Hemofil M & Recominate discontinuing mid 2026 Hurricane Helene Resources